Published in J Rheumatol on November 01, 1990
ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol (1993) 2.44
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55
The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore) (2013) 1.13
Anti-neutrophil cytoplasmic antibody-associated paraneoplastic vasculitis. Postgrad Med J (1994) 0.91
Malignancy risk in vasculitis. Ther Adv Musculoskelet Dis (2011) 0.87
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum (2011) 0.86
Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol (2008) 0.81
Adult Henoch-Schönlein purpura associated with small cell lung cancer: A case report and review of the literature. Oncol Lett (2013) 0.78
Update on paraneoplastic neurologic disorders. Oncologist (2010) 0.77
Henoch-Schönlein purpura as clinical presentation of a myelodysplastic syndrome. Clin Rheumatol (1997) 0.76
Development of multiple malignancies following long-term glucocorticoid therapy in a patient with leukocytoclastic vasculitis: A case report. Mol Clin Oncol (2016) 0.75
Vasculitis possibly confined to the small and large intestine. West J Med (1995) 0.75
Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. J Cancer Res Clin Oncol (2004) 0.75
Henoch-Schönlein Purpura with Concurrent Cytomegalovirus Duodenitis. Infect Chemother (2017) 0.75
Paraneoplastic vasculitis of central nervous system presenting as recurrent cryptogenic stroke. Int J Clin Oncol (2007) 0.75
[Vasculitides: classification, clinical aspects and pathology. A review]. Pathologe (2003) 0.75
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Drug-induced lupus syndromes. Mayo Clin Proc (1969) 3.38
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (1982) 3.10
Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol (1998) 2.17
Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood (2000) 2.09
Restoration of early thymocyte differentiation in T-cell receptor beta-chain-deficient mutant mice by transmembrane signaling through CD3 epsilon. Proc Natl Acad Sci U S A (1993) 2.06
Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote. J Nucl Cardiol (2014) 1.99
Drug-induced antinuclear antibodies and lupus syndromes. Drugs (1976) 1.93
Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Nature (1996) 1.87
B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med (1998) 1.85
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
18F-FDG PET/CT in the evaluation of POEMS syndrome. Eur J Radiol (2009) 1.74
The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR. Nat Genet (1993) 1.72
Control of starch composition and structure through substrate supply in the monocellular alga Chlamydomonas reinhardtii. J Biol Chem (1996) 1.67
Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax (2009) 1.65
Plasmid transformation in Bacillus subtilis: effects of insertion of Bacillus subtilis DNA into plasmid pC194. Mol Gen Genet (1981) 1.63
Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol (1990) 1.61
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol (1988) 1.58
The antiphospholipid/cofactor syndromes. J Rheumatol (1996) 1.57
Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol (1992) 1.56
Letter: Pre-Columbian representation of Heberden's nodes. Arthritis Rheum (1976) 1.56
Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med (2001) 1.55
Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore) (1967) 1.53
Gout nodulosis: widespread subcutaneous deposits without gout. Arthritis Care Res (1996) 1.53
Multivalent structure of an alphabetaT cell receptor. Proc Natl Acad Sci U S A (1999) 1.52
Development of lymphocytes in interleukin 7-transgenic mice. Eur J Immunol (1991) 1.49
Primary antiphospholipid syndrome as a cause of intestinal infarction. J Rheumatol (1992) 1.48
Transmission of HIV in dialysis centre. Lancet (1995) 1.47
Features of Sjögren's syndrome in primary biliary cirrhosis. Ann Intern Med (1973) 1.45
Course of antiphospholipid antibodies in patients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin. Relationship of antibody levels to outcome in 7 patients. J Rheumatol (1992) 1.43
The first descriptions of therapeutic arthrocentesis: a historical note. Rheumatology (Oxford) (2003) 1.42
Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3- natural killer cells subset. Blood (1993) 1.41
Autologous rosette-forming T cells as the responding cells in human autologous mixed-lymphocyte reaction. J Clin Invest (1980) 1.41
Tween 20 detaches cardiolipin from ELISA plates and makes anticardiolipin antibodies undetectable regardless of the presence of beta 2-glycoprotein-I. J Immunol Methods (1994) 1.41
Presence of a 16/6 related human anti-DNA common idiotype (SA1) in the anticardiolipin antibodies of patients with primary antiphospholipid syndrome. J Rheumatol (1991) 1.40
Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity. Clin Nephrol (2008) 1.40
Persistent lymphocytosis of natural killer cells in autoimmune thrombocytopenic purpura (ATP) patients after splenectomy. Br J Haematol (1995) 1.40
Young immunologist's finger. J Rheumatol (1989) 1.39
Will some day PAPS fade into SLE? Lupus (1996) 1.39
Listeriosis in patients with connective tissue diseases. J Rheumatol (1994) 1.39
Pulmonary injuries and cytokine levels after the intraperitoneal administration of pancreatic homogenates in rats. Rev Esp Enferm Dig (2004) 1.38
Irreversible acute renal failure after extracorporeal shock-wave lithotripsy. Nephron (1993) 1.38
[Geriatric information in the hospital discharge reports of patients over 65 years of age admitted to an Internal Medicine Department]. Rev Clin Esp (2004) 1.38
[Allergology in the public health service of the Community of Madrid: current situation and opportunities in the XXI century public health system]. An Sist Sanit Navar (2015) 1.37
Sjögren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med (1974) 1.37
Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc (2008) 1.37
Uracil-specific anti-R.N.A. antibodies in scleroderma. Lancet (1975) 1.36
Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus. J Clin Invest (1978) 1.34
Directed proteomics identifies a plant-specific protein rapidly phosphorylated in response to bacterial and fungal elicitors. Plant Cell (2001) 1.29
Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus (1996) 1.27
The range and specificity of antinuclear antibodies in systemic lupus erythematosus. Clin Exp Immunol (1970) 1.24
Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors. Mol Cell Biol (1988) 1.22
Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum (1978) 1.20
Regulation of CFTR expression and function during differentiation of intestinal epithelial cells. EMBO J (1992) 1.18
Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res (1996) 1.17
Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol (1995) 1.17
Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón). Am J Respir Crit Care Med (2001) 1.16
Mutations in the desert hedgehog (DHH) gene in patients with 46,XY complete pure gonadal dysgenesis. J Clin Endocrinol Metab (2004) 1.16
Articular manifestations of mixed connective tissue disease. Arthritis Rheum (1979) 1.16
The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med (1991) 1.14
Starch biosynthesis and its regulation. Biochem Soc Trans (1991) 1.14
Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol (1995) 1.14
Quadricuspid aortic valve associated with fibromuscular subaortic stenosis and aortic regurgitation treated by conservative surgery. Chest (1981) 1.13
Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol (1988) 1.12
Receptor and non-receptor-bearing lymphocytes in untreated systemic lupus erythematosus. Variations with disease activity. Rev Invest Clin (1978) 1.11
Procedure guidelines for radionuclide myocardial perfusion imaging. Heart (2004) 1.11
Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. HIV Med (2013) 1.10
Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis. Genes Immun (2004) 1.08
Plasmid transformation in Bacillus subtilis. Effects of the insertion of Bacillus subtilis rRNA genes into plasmids. Mol Gen Genet (1983) 1.08
Polyuronides in the cell walls of Mucor rouxii. Biochim Biophys Acta (1968) 1.08
Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus. Arthritis Rheum (1980) 1.07
Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid. Clin Exp Immunol (1969) 1.07
Sjögren's syndrome in systemic lupus erythematosus. Clinical and subclinical manifestations. Ann Intern Med (1974) 1.07
Systemic lupus erythematosus presenting as panniculitis (lupus profundus). Ann Intern Med (1975) 1.06
Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol (1994) 1.06
The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS (1992) 1.06
Takayasu arteritis in Colombia. Int J Cardiol (1998) 1.04
Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U). J Immunol (1975) 1.04
T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med (1995) 1.04
Myoclonus of peripheral origin: case secondary to a digital nerve lesion. Mov Disord (2001) 1.04
Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus. Clin Exp Immunol (1979) 1.04
Association of partial lipodystrophy and Sjögren's syndrome. Ann Intern Med (1976) 1.03
Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol (1992) 1.03
Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett (1998) 1.03
T-lymphocyte subpopulation in untreated SLE. Variations with disease activity. Arthritis Rheum (1977) 1.03
Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver. J Ethnopharmacol (1999) 1.02
Plasmid transformation in Bacillus subtilis. Alterations introduced into the recipient-homologous DNA of hybrid plasmids can be corrected in transformation. Mol Gen Genet (1981) 1.00
From benign polyclonal to malignant monoclonal lymphoproliferation in a patient with primary Sjögren's syndrome. Arthritis Rheum (1981) 1.00
Sense- and antisense-mediated gene silencing in tobacco is inhibited by the same viral suppressors and is associated with accumulation of small RNAs. Proc Natl Acad Sci U S A (2001) 1.00
Mixed gonadal dysgenesis: clinical, cytogenetic, endocrinological, and histopathological findings in 16 patients. Am J Med Genet (1993) 0.99
Autoantibody profile in African-American patients with lupus nephritis. Lupus (1996) 0.99
Oculocardiac reflex in sedated patients having laser in situ keratomileusis. J Cataract Refract Surg (1999) 0.98
Typhoid colitis with massive lower gastrointestinal bleeding. An unexpected behavior of Salmonella typhi. Dis Colon Rectum (1986) 0.98
Human postthymic precursor cells in health and disease. VII. Immunoregulatory circuits of the peripheral blood mononuclear cells from patients with progressive systemic sclerosis. J Clin Lab Immunol (1981) 0.98
Gene organization and transcription analysis of the Agrobacterium tumefaciens glycogen (glg) operon: two transcripts for the single phosphoglucomutase gene. J Bacteriol (1998) 0.98
Autoimmune thyroid disease in primary Sjögren's syndrome. Am J Med (1995) 0.97
The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology (1995) 0.97